Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDOptimizeRx Corporation Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 4 | -$0.11 | -$0.10 | -$0.10 |
| Q2 2025 | 7 | $0.02 | $0.02 | $0.02 |
| Q3 2025 | 5 | $0.04 | $0.04 | $0.04 |
| Q4 2025 | 5 | $0.20 | $0.24 | $0.22 |
| Q1 2026 | 4 | -$0.04 | $0.10 | $0.03 |
| Q2 2026 | 1 | $0.14 | $0.17 | $0.15 |
| Q3 2026 | 1 | $0.27 | $0.34 | $0.30 |
| Q4 2026 | 1 | $0.34 | $0.43 | $0.38 |
| Q1 2027 | 1 | $0.04 | $0.05 | $0.04 |
| Q2 2027 | 1 | $0.18 | $0.23 | $0.20 |
| Q3 2027 | 1 | $0.34 | $0.43 | $0.38 |
| Q4 2027 | 1 | $0.42 | $0.53 | $0.47 |
OptimizeRx Corporation Earnings Date And Information
OptimizeRx Corporation last posted its earnings results on Thursday, November 6th, 2025. The company reported $0.2 earnings per share for the quarter, topping analysts' consensus estimates of $0.03 by $0.17. The company had revenue of 26.07 M for the quarter and had revenue of 92.13 M for the year. OptimizeRx Corporation has generated $-1 earnings per share over the last year ($-1.1 diluted earnings per share) and currently has a price-to-earnings ratio of 7688.38. OptimizeRx Corporation has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 12th, 2025 based on prior year's report dates.
OptimizeRx Corporation Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2025 | Q3 2025 | N/A | $0.04 | N/A | $23.55 M | $26.07 M |
| 08/08/2025 | Q2 2025 | N/A | $0.08 | N/A | $22.26 M | $29.20 M |
| 05/13/2025 | Q1 2025 | N/A | -$0.12 | N/A | N/A | $21.93 M |
| 03/20/2025 | Q4 2024 | N/A | $0.00 | N/A | N/A | $32.32 M |
| 11/14/2024 | Q3 2024 | N/A | -$0.50 | N/A | $24.99 M | $21.31 M |
| 08/15/2024 | Q2 2024 | N/A | -$0.22 | N/A | $20.16 M | $18.81 M |
| 05/15/2024 | Q1 2024 | N/A | -$0.38 | N/A | N/A | $19.69 M |
| 04/15/2024 | Q4 2023 | N/A | -$0.23 | N/A | N/A | $28.37 M |
| 11/06/2023 | Q3 2023 | $0.03 | -$0.17 | -0.2 | $15.14 M | $16.33 M |
| 08/14/2023 | Q2 2023 | -$0.01 | -$0.24 | -0.23 | $14.80 M | $13.82 M |
| 05/12/2023 | Q1 2023 | N/A | -$0.37 | N/A | $12.35 M | $13.00 M |
| 03/10/2023 | Q4 2022 | N/A | -$0.02 | N/A | $21.77 M | $19.65 M |
| 03/10/2023 | Q3 2022 | N/A | -$0.19 | N/A | $14.92 M | $15.09 M |
| 03/10/2023 | Q2 2022 | N/A | -$0.21 | N/A | $17.06 M | $13.98 M |
| 03/10/2023 | Q1 2022 | N/A | -$0.21 | N/A | $13.55 M | $13.73 M |
| 03/10/2023 | Q4 2021 | N/A | $0.04 | N/A | $20.16 M | $20.31 M |
| 11/09/2021 | Q3 2021 | $0.13 | $0.00 | -0.13 | $15.14 M | $16.12 M |
| 08/04/2021 | Q2 2021 | $0.07 | $0.02 | -0.05 | $12.45 M | $13.63 M |
| 05/06/2021 | Q1 2021 | $0.01 | -$0.04 | -0.05 | $10.47 M | $11.23 M |
| 03/08/2021 | Q4 2020 | N/A | $0.09 | N/A | $16.01 M | $16.43 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
OptimizeRx Corporation Earnings: FAQ's
OptimizeRx Corporation has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 12th, 2025 based offlast year's report dates.
In the previous quarter, OptimizeRx Corporation (:OPRX) reported $0.2 earnings per share (EPS) to beat the analysts' consensus estimate of $0.03 by $0.17.
The conference call for OptimizeRx Corporation's latest earnings report can be listened to online.
The conference call transcript for OptimizeRx Corporation's latest earnings report can be read online.
OptimizeRx Corporation (:OPRX) has a recorded annual revenue of $92.13 M.
OptimizeRx Corporation (:OPRX) has a recorded net income of $-20,110,000.OptimizeRx Corporation has generated $-1.1 earnings per share over the last four quarters.
OptimizeRx Corporation (:OPRX) has a price-to-earnings ratio of 7688.38 and price/earnings-to-growth ratio is 77.08.